TRPA1 and diabetic neuropathy: A phase two randomized, controlled, double-blinded clinical trial evaluating the TRPA1 blocker ISC-17536 (Glenmark Pharmaceuticals) as monotherapy for painful diabetic neuropathy was published recently (Agarwal et al., 2014).